Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)
CMS-001 trial is the first and only double-blinded, placebo-controlled study ever conducted in genetically confirmed CMS patients
Results in full population across all tested subtypes of CMS did not achieve statistical significance for the primary or secondary endpoints
MuSK-Myasthenia Gravis Phase 3 trial and SMA Type-3 proof of concept study both remain on schedule
CMS-001 is the first ever double-blind, placebo-controlled, clinical trial conducted in genetically confirmed CMS patients. In the trial, 20 subjects were enrolled and 16 randomized, in a 2 period, 2 treatment crossover study designed to evaluate the efficacy and safety of amifampridine phosphate in patients (aged 2 years and above) diagnosed with certain genetic subtypes of CMS. While individual patient improvements were observed in some patient sub-groups, the trial did not meet its primary endpoint of subject global impression (SGI) or the secondary endpoint of muscle function measure (MFM) across all tested subtypes. Due to the rarity of CMS, this trial took almost 4 years to recruit.
“While we are disappointed that this trial did not reach its primary or secondary endpoints in the evaluated CMS patient subtypes, we are pleased with the new valuable clinical information that these results will provide to the medical and scientific communities as we work to develop
Catalyst is scheduled to meet with the
The Company also reports that it remains on track to complete enrollment in its clinical trial of amifampridine phosphate in patients with anti-MuSK antibody positive myasthenia gravis (MuSK-MG) before the end of this year, and to report top-line data from this trial in the first half of 2020. We also expect to report top-line results from our SMA Type-3 proof of concept study in the first half of 2020. Both of these diseases have a much more homogeneous patient population than CMS and should not present the same challenges.
“We have made significant progress in genetically testing patients who were unable to previously get diagnosed,” added
About Congenital Myasthenic Syndromes (CMS)
Congenital myasthenic syndromes, or CMS, are rare neuromuscular disorders comprising a spectrum of more than 50 genetic defects with some of the various mutations having as few as a handful of diagnosed patients. CMS patients are characterized by fatigable weakness of skeletal muscles with onset at or shortly after birth or early childhood; in rare cases, symptoms may not manifest themselves until later in childhood. The severity and course of the genetic disease types are variable, ranging from minor symptoms to progressive disabling weakness; symptoms may be mild, but sudden severe exacerbations of weakness or even sudden episodes of respiratory insufficiency also occur.
CMS is rare. Catalyst estimates that there are between 1,000 and 1,500 CMS patients in
About MuSK Myasthenia Gravis (MuSK—MG)
About 15% of Myasthenia Gravis, or MG, patients test negative for the acetylcholine receptor antibody, and about 40-50% of these "seronegative MG" patients are test positive for the MuSK-MG antibody and are identified as MuSK-MG patients, representing about 4,500 patients in
Firdapse is currently being evaluated in clinical trials for the treatment of MuSK-MG, CMS, and SMA Type 3 and has received Orphan Drug Designation from the FDA for myasthenia gravis and CMS. Firdapse (amifampridine) 10 mg tablets is the first and only approved drug in Europe for the symptomatic treatment in adults with LEMS.
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including (i) whether the
Patrick J. McEnany
Chief Executive Officer
Source: Catalyst Pharmaceuticals, Inc.